An Open-Label, Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial formulation â?? Habb-e-Karanjawa in Humma (Fever)

Central Council for Research in Unani Medicine CCRUM New Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Participants of either sex in the age group 18 to 60 years
•2. History of onset of fever within 24 hr
•3. Participants with oral temperature >=100 0F presenting with any of the following symptoms:
•Joints pain
•Palpitation
•Skin Flushing

•1. Intake of any antipyretic drugs in the previous 8 hrs.
•2. Participant having oral temperature of >= 1040F
•3. Known high risk clinical conditions such as pneumonia, sepsis, dengue haemorrhagic fever,meningitis, hepatitis B, etc.
•4. Immuno-compromised clinical conditions such as HIV/AIDS, cancer, etc.
•5. Known cases of other clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) that in the opinion of the investigator could affect the efficacy and safety outcome of the study.
•6. Thrombocytopaenia defined as absolute platelet count below 50000/ cu.mm.
•7. Known hypersensitivity to study drug or any of its ingredients
•8. Pregnant and Lactating females

发起方

Central Council for Research in Unani Medicine CCRUM New Delhi